title: Erythema nodosum associated with infliximab therapy.
abstract: A number of unrelated cutaneous adverse events have been rarely associated with administration of infliximab. This drug has been used to control erythema nodosum when the latter was associated with Crohn disease. We herein report the paradoxical occurrence of erythema nodosum, verified by repeated challenges, following infliximab infusion given for ankylosing spondylitis. Despite this side effect, the patient elected to continue therapy due to a high degree of efficacy.
authors.affiliation: Department of Dermatology, Baylor College of Medicine, Houston, TX, USA. vampireted@aol.com
authors.forename: Ted
authors.initials: T
authors.lastname: Rosen
authors.forename: Paul
authors.initials: P
authors.lastname: Martinelli
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D004893:Erythema Nodosum / Q000139:chemically induced* / Q000473:pathology; D005528:Foot / Q000473:pathology; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D012867:Skin / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab